This page shows the latest sunitinib news and features for those working in and with pharma, biotech and healthcare.
In June, Merck and Eisai also announced that the Keytruda plus Lenvima combination treatment improved outcomes when compared to Pfizer’s Sutent (sunitinib) on a measure of health-related quality of ... Previously, Merck and Eisai reported that Keytruda
Novartis’ Afinitor (everolimus) versus Sutent (sunitinib) for the first-line treatment of advanced RCC patients. ... Previously, Merck and Eisai reported that Keytruda and Lenvima met the primary endpoint of improved progression-free survival (PFS)
older TKI Sutent (sunitinib) in patients with advanced RCC.
In this study, checkpoint inhibitor Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and Lenvima plus everolimus were compared to Pfizer’s tyrosine kinase inhibitor (TKI) Sutent (sunitinib) for the first-line treatment of
sunitinib) in the first-line treatment of advanced renal cell carcinoma (RCC) – the most common type of kidney cancer in adults.
This approval is based on results from the phase 3 CheckMate-9ER trial, which compared Opdivo plus Cabometyx to Pfizer’s older tyrosine kinase inhibitor (TKI) Sutent (sunitinib) in patients with
More from news
Approximately 2 fully matching, plus 76 partially matching documents found.
The verdict followed another recent win, that this time saw it granted permission to market a generic version of Pfizer's Sutent (sunitinib malate) after challenging the drug's patent.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate
Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines. ... Consistent with EMA market authorisations for other kidney cancer
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....